Company Filing History:
Years Active: 2019-2020
Title: Innovations by Adele Blackler
Introduction
Adele Blackler is a prominent inventor based in Rockville, MD, known for her significant contributions to the field of biotechnology. With a total of three patents to her name, she has made remarkable advancements in the quantification of proteins and the treatment of breast cancer.
Latest Patents
One of her latest patents focuses on the SRM/MRM assay for the tyrosine-protein kinase receptor UFO (AXL) protein. This patent provides specific peptides and their ionization characteristics, which are advantageous for quantifying the AXL protein directly in biological samples fixed in formalin. The method utilizes Selected Reaction Monitoring (SRM) mass spectrometry, allowing for the quantitation of AXL protein in various biological samples, including formalin-fixed tissues and cells. Another notable patent involves methods for treating Her2-positive breast cancer. This patent outlines a quantitative Her2 assay that identifies whether a breast tumor will respond to anti-Her2 therapeutic agents, enabling the selection of suitable treatment regimens.
Career Highlights
Adele Blackler is currently associated with Expression Pathology Incorporated, where she continues to innovate in the field of cancer research and diagnostics. Her work has been instrumental in developing methods that enhance the accuracy of cancer treatment protocols.
Collaborations
Adele collaborates with notable professionals in her field, including Todd Hembrough and David B Krizman. Their combined expertise contributes to the advancement of innovative solutions in biotechnology.
Conclusion
Adele Blackler's contributions to biotechnology, particularly in cancer diagnostics and treatment, highlight her role as a leading inventor in her field. Her patents reflect a commitment to improving patient outcomes through innovative research and development.